CA2028610A1 - Triazolo derivatives and process for their preparation - Google Patents

Triazolo derivatives and process for their preparation

Info

Publication number
CA2028610A1
CA2028610A1 CA002028610A CA2028610A CA2028610A1 CA 2028610 A1 CA2028610 A1 CA 2028610A1 CA 002028610 A CA002028610 A CA 002028610A CA 2028610 A CA2028610 A CA 2028610A CA 2028610 A1 CA2028610 A1 CA 2028610A1
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
methyl
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002028610A
Other languages
English (en)
French (fr)
Inventor
Jozsef Reiter
Jozsef Barkoczy
Luiza Petocz
Frigyes Gorgenyi
Marton Fekete
Eniko Szirt
Gabor Gigler
Istvan Gacsalyi
Istvan Gyertyan
Klara Reiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU542789A external-priority patent/HU206094B/hu
Priority claimed from HU542989A external-priority patent/HU205357B/hu
Application filed by Individual filed Critical Individual
Publication of CA2028610A1 publication Critical patent/CA2028610A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002028610A 1989-10-25 1990-10-25 Triazolo derivatives and process for their preparation Abandoned CA2028610A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HU5427/89 1989-10-25
HU542789A HU206094B (en) 1989-10-25 1989-10-25 Process for producing triazolylcarboxylic acid hydrazone derivatives and pharmaceutical compositions comprising same
HU5429/89 1989-10-25
HU542989A HU205357B (en) 1989-10-25 1989-10-25 Process for producing tetrahydro-triazolo-tetrazepine derivatives and pharmaceutical compositions comprising same

Publications (1)

Publication Number Publication Date
CA2028610A1 true CA2028610A1 (en) 1991-04-26

Family

ID=26317835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002028610A Abandoned CA2028610A1 (en) 1989-10-25 1990-10-25 Triazolo derivatives and process for their preparation

Country Status (11)

Country Link
US (1) US5135928A (2)
EP (1) EP0425282A3 (2)
JP (1) JPH03209369A (2)
KR (1) KR910007894A (2)
BG (1) BG51043A3 (2)
CA (1) CA2028610A1 (2)
FI (1) FI905255A7 (2)
IL (1) IL96127A0 (2)
IN (1) IN171609B (2)
PL (1) PL164805B1 (2)
YU (1) YU201090A (2)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003286A1 (en) * 1993-07-23 1995-02-02 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR100986904B1 (ko) * 2008-11-10 2010-10-08 한국항공우주산업 주식회사 일체형 전단 및 굽힘 시험 장치
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352944A (en) * 1942-07-04 1944-07-04 Gen Electric Triazole derivatives
GB949170A (en) * 1960-03-15 1964-02-12 France Etat Carbamyl and thiocarbamyl substances, methods for producing same and applications thereof
US4144233A (en) * 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines

Also Published As

Publication number Publication date
FI905255A7 (fi) 1991-04-26
YU201090A (sh) 1993-05-28
US5135928A (en) 1992-08-04
PL164805B1 (pl) 1994-10-31
EP0425282A3 (en) 1991-10-16
PL287505A1 (en) 1991-07-29
BG51043A3 (bg) 1993-01-15
EP0425282A2 (en) 1991-05-02
KR910007894A (ko) 1991-05-30
JPH03209369A (ja) 1991-09-12
FI905255A0 (fi) 1990-10-25
IL96127A0 (en) 1991-07-18
IN171609B (2) 1992-11-21

Similar Documents

Publication Publication Date Title
CA2350538C (en) Pyrazolopyrimidinone derivatives for the treatment of impotence
US5502187A (en) Pharmaceutically active bicyclic-heterocyclic amines
AU716383B2 (en) Novel N-7-heterocyclyl pyrrolo(2,3-d)pyrimidines and the use thereof
AU2003268212B2 (en) Novel polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-YL}phenyl)acetamide and compositions and methods related thereto
AU5418896A (en) 6-substituted pyrazolo {3,4-d} pyrimidin-4-ones and compositions and methods of use thereof
WO1997028161A1 (en) Novel pyrrolo[2,3-d]pyrimidines and their use as tyrosine kinase inhibitors
JPS62155278A (ja) 複素環式化合物、その製法および使用
JP2001504109A (ja) ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途
EP0491218A1 (en) Benzodiazepinones
CA2037812A1 (fr) Derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant
HU204052B (en) Process for producing imidazopyridazines and pharmaceutical comprising such compounds
WO1997025329A1 (fr) DERIVES DE 5H,10H-IMIDAZO[1,2-a]INDOLO[3,2-e]PYRAZINE-4-ONE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
US4379155A (en) 3,5-Disubstituted-1H-1,2,4-triazole derivatives
HU192653B (en) Process for the production of imidazo /1,2-c/pyrimidines, as well as of therapeutic preparations containing these compounds as agent
US4562189A (en) Pyrazolylpiperazines
FI64150B (fi) Nya vid foedelsekontroll av daeggdjur anvaendbara 3,5-disubstituerade 1h-1,2,4-triazoler
EP0197230B1 (fr) Imidazo /1,2-a/ pyrimidines et leurs sels avec les acides, procédé et intermédiaires de préparation, application comme médicaments et compositions les renfermant
US4602015A (en) 2-piperazinopyrimidine salt and pharmaceutical compositions containing it
WO1996002544A1 (fr) DERIVES D'ACIDE IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-2-CARBOXYLIQUE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
US4086348A (en) Naphthyridine derivatives
CN116406364A (zh) 用于治疗红细胞障碍和炎性疾病的四氢异喹啉衍生物
RU2802300C1 (ru) ПРОТИВОТУБЕРКУЛЕЗНЫЕ АГЕНТЫ, ПРЕДСТАВЛЯЮЩИЕ СОБОЙ 3,7-ДИЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-b][1,2,4,5]ТЕТРАЗИНЫ
CA1329594C (en) 5-(substituted)amino)-8-(phenyl or substituted phenyl)-3h,6h-1,4,5a,8a-tetraazaacenaphthyen-3-ones
EP0425282A2 (en) Triazolo derivatives and process for their preparation
EP0030038B1 (en) 1,2,4-triazine derivatives, process for their production and pharmaceutical composition

Legal Events

Date Code Title Description
FZDE Discontinued